STOCK TITAN
  1. Home
  2. Sec-filings
  3. CYTK
  4. [Form 4] CYTOKINETICS INC Insider Trading Activity

Director at Cytokinetics (NASDAQ: CYTK) gets new stock and option grants

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

CYTOKINETICS INC director Robert E. Landry reported equity grants. He received 2,851 shares of Common Stock at no cost, increasing his direct holdings to 10,184 shares. He was also granted a non-qualified stock option for 4,301 shares at an exercise price of $77.15, exercisable starting on June 27, 2026 and expiring on May 26, 2036.

Positive

  • None.

Negative

  • None.
Insider Landry Robert E
Role null
Type Security Shares Price Value
Grant/Award Non-Qualified Stock Option (Right to Buy) 4,301 $0.00 --
Grant/Award Common Stock 2,851 $0.00 --
Holdings After Transaction: Non-Qualified Stock Option (Right to Buy) — 4,301 shares (Direct, null); Common Stock — 10,184 shares (Direct, null)
Footnotes (1)
Common Stock grant 2,851 shares Award of Common Stock on May 27, 2026
Shares held after grant 10,184 shares Direct Common Stock holdings following the transaction
Option grant size 4,301 options Non-qualified stock option for Common Stock
Option exercise price $77.15 per share Conversion or exercise price of non-qualified stock option
Option vesting date June 27, 2026 Exercise date when option first becomes exercisable
Option expiration May 26, 2036 Expiration date of non-qualified stock option
Non-Qualified Stock Option (Right to Buy) financial
"security_title: "Non-Qualified Stock Option (Right to Buy)""
derivative financial
"transaction_type: "derivative" for the stock option grant"
A derivative is a financial contract whose value depends on the price or performance of another asset or measure — for example a stock, index, interest rate, commodity, or currency. Investors use derivatives like insurance or leveraged bets to hedge risk, speculate, or gain exposure without owning the underlying asset; they can protect portfolios but also amplify losses and introduce counterparty and market risk.
exercise price financial
"conversion_or_exercise_price: "77.1500" for the option"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
Grant, award, or other acquisition financial
"transaction_code_description: "Grant, award, or other acquisition""
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Landry Robert E
(Last)(First)(Middle)
350 OYSTER POINT BLVD
(Street)
SOUTH SAN FRANCISCO CALIFORNIA 94580
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
CYTOKINETICS INC [ CYTK ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
05/27/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock05/27/2026A2,851A$010,184D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Non-Qualified Stock Option (Right to Buy)$77.1505/27/2026A4,30106/27/202605/26/2036Common Stock4,301$04,301D
Explanation of Responses:
/s/ John O. Faurescu, attorney-in-fact for Mr. Landry05/27/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did CYTK director Robert E. Landry report?

Robert E. Landry reported receiving equity awards in Cytokinetics. He was granted 2,851 shares of Common Stock and a non-qualified stock option for 4,301 shares, both recorded as awards rather than open-market purchases or sales.

How many CYTK common shares does Robert E. Landry now hold directly?

After the reported grant, Robert E. Landry directly holds 10,184 shares of Cytokinetics Common Stock. This reflects the addition of 2,851 granted shares, which were acquired at no cash cost as part of his director compensation.

What are the key terms of Robert E. Landry’s CYTK stock option grant?

Landry received a non-qualified stock option covering 4,301 Cytokinetics shares at an exercise price of $77.15. The option becomes exercisable on June 27, 2026 and expires on May 26, 2036, giving a long-dated right to buy shares at that fixed price.

Was Robert E. Landry’s CYTK Form 4 a market buy or sell?

The Form 4 reports grant or award acquisitions, not market trades. Both the 2,851 Common Stock shares and the 4,301-share option were recorded under code “A” for awards, meaning they were compensation-related, not open-market buying or selling activity.

Does the CYTK Form 4 show any derivative positions for Robert E. Landry?

Yes. The filing shows Landry was granted a derivative security: a non-qualified stock option for 4,301 shares of Common Stock at $77.15. Following this grant, his total reported holdings of this option class are 4,301 derivative securities.